Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 254 participants.
Also called NCT02057172
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 254 participants
- Registry
-
NCT02057172
-
- Other papers using this trial's data
- Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02057172. Randomized; triple masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2014-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- HM11260C
- Intervention (Drug)
- liraglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
Record details
- Record id
cardio:ct-nct02057172- Content hash
3e3d8bf33cca0e87af4534d5c890be0053dad7f0e59bfb8727d6a55ef8aa3974